Effects of long-term magnesium supplementation on endothelial function and cardiometabolic risk markers: A randomized controlled trial in overweight/obese adults
Joris PJ, Plat J, Bakker SJ, Mensink RP
Scientific reports · 32 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Possibly industry funded
Based on full-text disclosure statement.
Publication
- Published
- 2017-03-01 · Sci Rep · vol. 7 · issue 1 · p. 106
- Publisher
- Nature Portfolio
- Cited
- 48 citations · more than 90% of similar papers · 2.3× the field average
- References
- 44 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Cardiovascular Health and Disease Prevention · Magnesium in Health and Disease · Parathyroid Disorders and Treatments
- Keywords
- Medicine, Arterial stiffness, Overweight, Brachial artery, Internal medicine, Reactive hyperemia, Endothelial dysfunction, Placebo, Randomized controlled trial, Body mass index, Endocrinology, Endothelium, Type 2 diabetes, Diabetes mellitus, Vasodilation, Cardiology, Blood pressure, Pathology
- MeSH
- brachial artery, humans, obesity, magnesium, double-blind method, postmenopause, vasodilation, dietary supplements, aged, middle aged, female, male, overweight, vascular stiffness, biomarkers
4 authors
From NL, US
- Peter J. Joris · correspondingMaastricht University Medical Centre; University Medical Center; Maastricht University; TiFN
- Jogchum PlatUniversity Medical Center; Maastricht University
- Stephan J. L. BakkerUniversity Medical Center Groningen; University of Groningen
- Ronald P. MensinkUniversity Medical Center; Maastricht University; TiFN
Abstract
Long-term magnesium supplementation improves arterial stiffness, a cardiovascular disease risk marker. Effects on endothelial function may be another mechanism whereby increased magnesium intakes affect cardiovascular risk. Therefore, a 24-week, randomized, double-blind, placebo-controlled trial was performed to examine effects of magnesium supplementation on endothelial function and cardiometabolic risk markers. Fifty-two overweight and obese subjects (30 men and 22 women, age 62 ± 6 years) were randomized to receive either three times daily magnesium (total dose: 350 mg) or placebo capsules. Endothelial function was assessed at the start and at the end of the study. Cardiometabolic risk markers were measured at baseline, after 12 weeks, and at week 24. Brachial artery flow-mediated vasodilation did not change following long-term magnesium supplementation (0.49 pp; 95% CI: -0.38 to 1.36 pp; P = 0.26). Changes in reactive hyperemia index, retinal microvascular caliber and plasma markers for microvascular endothelial function (sVCAM-1, sICAM-1 and sE-selectin) were also not different. In addition, no effects on serum lipids, plasma glucose, insulin sensitivity, and low-grade systemic inflammation were observed. In conclusion, a daily magnesium supplement of 350 mg for 24 weeks does not improve endothelial function and cardiometabolic risk markers in overweight and obese middle-aged and elderly adults.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.